Prihlásiť sa Zaregistrujte sa zadarmo

Pomer krátenia spoločnosti Inhibrx

Aká je hodnota metriky Pomer krátenia spoločnosti Inhibrx?

Hodnota metriky Pomer krátenia spoločnosti Inhibrx, Inc. je 9.24

Aká je definícia metriky Pomer krátenia?



Pomer krátenia (Short ratio) je pomer akcií predaných na krátko a priemerným denným objemom.

Short ratio is calculated by dividing the number of shares sold short by the average daily trading volume, generally over the last 30 trading days. The ratio represents the number of days it takes short sellers on average to repurchase all the borrowed shares. The ratio is used by both fundamental and technical traders to identify trends.

The percentage represents the number of days it takes short sellers on average to repurchase all the borrowed shares. Short selling is the practice of selling securities or other financial instruments that are not currently owned, and subsequently repurchasing them. In the event of an interim price decline, the short seller profits, since the cost of (re)purchase is less than the proceeds received upon the initial (short) sale. Conversely, the short position closes out at a loss if the price of a shorted instrument rises prior to repurchase. A high short ratio can be an indicator that there will be some buying pressure on the security that would increase its price.

Pomer krátenia spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Inhibrx

Čomu sa venuje spoločnosť Inhibrx?

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.

Firmy s metrikou pomer krátenia podobnou spoločnosti Inhibrx



  • Hodnota metriky Pomer krátenia spoločnosti Xenon Pharmaceuticals Inc je 9.22
  • Hodnota metriky Pomer krátenia spoločnosti German American Bancorp Inc je 9.22
  • Hodnota metriky Pomer krátenia spoločnosti 908 Devices je 9.22
  • Hodnota metriky Pomer krátenia spoločnosti Metro je 9.23
  • Hodnota metriky Pomer krátenia spoločnosti Pros Inc je 9.23
  • Hodnota metriky Pomer krátenia spoločnosti Target Hospitality je 9.23
  • Hodnota metriky Pomer krátenia spoločnosti Inhibrx je 9.24
  • Hodnota metriky Pomer krátenia spoločnosti Beyond Meat Inc je 9.26
  • Hodnota metriky Pomer krátenia spoločnosti Neonode je 9.27
  • Hodnota metriky Pomer krátenia spoločnosti Becton, Dickinson and je 9.27
  • Hodnota metriky Pomer krátenia spoločnosti Camtek Ltd je 9.28
  • Hodnota metriky Pomer krátenia spoločnosti BRC je 9.28
  • Hodnota metriky Pomer krátenia spoločnosti 1 Automotive je 9.28